M. Mandić

发表

Demonstration of a Direct Interaction between β2-Adrenergic Receptor and Insulin Receptor by BRET and Bioinformatics

N. Veljkovic, M. Mandić, L. Drinovec, 2014, PloS one.

Enhancement in Specific CD8+ T Cell Recognition of EphA2+ Tumors In Vitro and In Vivo after Treatment with Ligand Agonists1

J. Finke, M. Kinch, E. Bruckheimer, 2008, The Journal of Immunology.

Enhancement in Specific CD 8 T Cell Recognition of EphA 2 Tumors In Vitro and In Vivo after Treatment with Ligand Agonists 1

J. Finke, M. Kinch, E. Bruckheimer, 2008 .

Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling.

H. Zarour, M. Mandić, A. Lokshin, 2007, Cancer research.

Circulating Type-1 Anti-Tumor CD4+ T Cells are Preferentially Pro-Apoptotic in Cancer Patients

J. Kirkwood, J. Finke, M. Mandić, 2014, Front. Oncol..

Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells.

L. Neckers, M. Mandić, Jennifer L. Taylor, 2009, Cancer research.

Heat Shock Protein 90 Inhibitor 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin Enhances EphA 2 + Tumor Cell Recognition by Specific CD 8 + T Cells

L. Neckers, M. Mandić, Jennifer L. Taylor, 2009 .

Focus on FOCIS: interleukin 2 treatment associated autoimmunity.

J. Kirkwood, M. Lotze, M. Mandić, 2008, Clinical immunology.

One NY-ESO-1-Derived Epitope That Promiscuously Binds to Multiple HLA-DR and HLA-DP4 Molecules and Stimulates Autologous CD4+ T Cells from Patients with NY-ESO-1-Expressing Melanoma1

V. Brusic, J. Kirkwood, H. Zarour, 2005, The Journal of Immunology.

NY-ESO-1-Expressing Melanoma T Cells from Patients with + Autologous CD 4 and HLA-DP 4 Molecules and Stimulates Promiscuously Binds to Multiple HLA-DR One NY-ESO-1-Derived Epitope That

V. Brusic, J. Kirkwood, H. Zarour, 2005 .

Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Common Problem Drugs and How to Prescribe Them

B. Meibohm, M. Mandić, J. N. van den Anker, 2019, Journal of clinical pharmacology.

A Mycoplasma Peptide Elicits Heteroclitic CD4+ T Cell Responses against Tumor Antigen MAGE-A6

J. Kirkwood, W. Olson, M. Mandić, 2007, Clinical Cancer Research.

Cardiopulmonary metastrongyloidosis of dogs and cats contribution to diagnose

M. Mandić, T. Ilic, S. Dimitrijević, 2017 .

Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Biologics

B. Meibohm, M. Mandić, J. Korth-Bradley, 2017, Journal of clinical pharmacology.

SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas

D. Jukic, J. Kirkwood, C. Athanassiou, 2007, Oncogene.

Dog and cat respiratory capilariasis - clinical, parasitological and epidemiological significance

M. Mandić, S. Dimitrijević, P. Stepanović, 2015 .

Interferon-alpha (IFN-α)–conditioned DC Preferentially Stimulate Type-1 and Limit Treg-type In Vitro T-cell Responses From RCC Patients

M. Dambrosio, L. Gesualdo, E. Ranieri, 2008, Journal of immunotherapy.

The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.

Daniel Gillet, Christine Almunia, Bernard Maillere, 2003, Cancer research.

Pharmacodynamic (Phase 0) Study Using Etaracizumab in Advanced Melanoma

Manuela Buzoianu, Charalambos Athanassiou, Drazen M Jukic, 2010, Journal of immunotherapy.

Dosage Adjustments Related to Young or Old Age and Organ Impairment

M. Mandić, M. Tortorici, M. Reed, 2016, Journal of clinical pharmacology.